Dr. Alex Morgan brings a broad analytical perspective to biotechnology, healthcare innovation, and life sciences strategy. With experience spanning research, industry analysis, and market intelligence, Alex examines how scientific progress, capital flows, and policy decisions intersect. At The Catalyst Brief, Alex focuses on connecting developments across domains to surface the strategic implications that matter most to industry leaders.
134 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Healthcare InvestmentThe health tech sector continues its upward trajectory with robust funding rounds reported in February 2026. This article highlights five notable investments that reflect the evolving landscape where technology is reshaping healthcare delivery and patient management.
Dr. Alex MorganMar 3, 2026
Biopharmaceutical IndustryIn less than a year, BioAtla has doubled its staff reductions, shedding an even greater portion of its workforce. This drastic move signals significant shifts within the company as it evaluates various strategic pathways to sustain its operations and maintain a competitive edge in the dynamic biotech sector.
Dr. Alex MorganMar 2, 2026
AI in Drug DiscoveryThe evolving healthcare ecosystem in 2026 is underscored by the increasing adoption of artificial intelligence to streamline administrative processes and strategic partnerships that boost therapeutic pipelines. This article analyzes recent developments and assesses their broader impact on the industry’s innovation trajectory and operational excellence.
Dr. Alex MorganFeb 27, 2026
Biopharmaceutical IndustryContract work is increasingly favored among biopharma employers and professionals alike. This article examines the growth of contract roles based on BioSpace data and features insights from three industry professionals sharing their experiences, benefits, and challenges with contracting.
Dr. Alex MorganFeb 26, 2026
AI in Drug DiscoveryThis collaboration between Mayo Clinic and Merck represents a critical advancement in applying artificial intelligence to healthcare data, with an ambitious goal to improve the accuracy and utility of prognostic models. Leveraging patient data for AI training promises to facilitate earlier diagnosis and personalized treatment interventions across a spectrum of diseases.
Dr. Alex MorganFeb 25, 2026
Healthcare InvestmentFrist Cressey Ventures recently secured $425 million in its fourth fund to back promising early-stage healthcare startups. The fund targets companies leveraging artificial intelligence to enhance healthcare delivery, reduce costs, and address challenges related to the aging population.
Dr. Alex MorganFeb 20, 2026
Healthcare InvestmentThis initiative marks a significant stride in connecting patients with holistic digital mental health, coaching, and therapy services offered by Calm and Lyra Health. The network aims to address growing behavioral health needs through accessible and innovative digital platforms.
Dr. Alex MorganFeb 19, 2026
Regulatory & PolicyThe journey of bitopertin, a drug targeting erythropoietic protoporphyria, illustrates the hurdles biotech companies face in regulatory pathways, especially when protocols are crafted with insights from previous FDA leaders. This article analyzes the implications of such influences on approval prospects and the innovation landscape in rare disease treatments.
Dr. Alex MorganFeb 17, 2026
Biotech InnovationRecent clinical results from Compass Pathways suggest that psilocybin-based medicines might soon gain regulatory approval for treating severe depression. These pioneering trials mark a hopeful step towards integrating psychedelic compounds into mainstream mental health care.
Dr. Alex MorganFeb 17, 2026
Biopharmaceutical IndustryThe fetal bovine serum shortage is posing significant supply chain challenges across the biopharma sector. This article analyzes the implications of the squeeze on drug prices and discusses mitigation strategies companies can adopt to reduce impact.
Dr. Alex MorganFeb 17, 2026
Regulatory & PolicyDisc Medicine’s recent setback with its rare disease therapy approval accentuates the hurdles faced by developers within the rare disease space. Regulatory scrutiny remains stringent as agencies balance patient needs with safety and efficacy standards.
Dr. Alex MorganFeb 15, 2026
Regulatory & PolicyA high-profile courtroom dispute unfolded involving pediatricians' group contesting policy alterations made by HHS under Robert F. Kennedy Jr. The case centers on alleged unlawful modifications impacting vaccine protocols, sparking significant debate within public health and policy circles.
Dr. Alex MorganFeb 14, 2026